Kevin R.
Filed with the SEC on · Summarized by InvestorsBot
Kevin R. Sayer returned from a temporary leave and resumed his role as Executive Chairman of DexCom effective Mar 2, 2026 (he retired as CEO on Jan 1, 2026). Mark Foletta resumed Lead Independent Director duties. $DXCM 🧑⚖️📅 #corporategovernance #healthtech
Under a letter agreement effective Mar 2, 2026, Sayer’s annual base salary is $610,000 and he was granted RSUs with a fair value of $2,350,000 that vest in full on Mar 8, 2027 (subject to continued service). Prior awards continue to vest. $DXCM 💰 #executivecomp #insider
Sayer remains eligible for DexCom’s standard executive benefit plans but is no longer eligible for the Company’s Amended & Restated Severance & Change in Control Plan as an executive officer. $DXCM ⚠️ #corporategovernance #risk